Ouro Fino Saúde Animal Participações

BOVESPA:OFSA3 Stock Report

Mkt Cap: R$1.2b

We’ve recently updated our valuation analysis.

Ouro Fino Saúde Animal Participações Valuation

Is OFSA3 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OFSA3?

Other financial metrics that can be useful for relative valuation.

OFSA3 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue1.5x
Enterprise Value/EBITDA9.5x
PEG Ration/a

Price to Earnings Ratio vs Peers

How does OFSA3's PE Ratio compare to its peers?

OFSA3 PE Ratio vs Peers
The above table shows the PE ratio for OFSA3 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPEEstimated GrowthMarket Cap
Peer Average14.7x
HYPE3 Hypera
17.1x17.1%R$28.0b
BLAU3 Blau Farmacêutica
18.6x17.5%R$5.8b
ABOT Abbott Laboratories (Pakistan)
12.8xn/aPK₨57.3b
524404 Marksans Pharma
10.2xn/a₹18.8b
OFSA3 Ouro Fino Saúde Animal Participações
10.9xn/aR$1.2b

Price-To-Earnings vs Peers: OFSA3 is good value based on its Price-To-Earnings Ratio (10.9x) compared to the peer average (14.7x).


Price to Earnings Ratio vs Industry

How does OFSA3's PE Ratio compare vs other companies in the Global Pharmaceuticals Industry?

Price-To-Earnings vs Industry: OFSA3 is good value based on its Price-To-Earnings Ratio (10.9x) compared to the Global Pharmaceuticals industry average (20.4x)


Price to Earnings Ratio vs Fair Ratio

What is OFSA3's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OFSA3 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio10.9x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate OFSA3's Price-To-Earnings Fair Ratio for valuation analysis.


Share Price vs Fair Value

What is the Fair Price of OFSA3 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OFSA3 (R$22.74) is trading above our estimate of fair value (R$0.54)

Significantly Below Fair Value: OFSA3 is trading above our estimate of fair value.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.


Discover undervalued companies